Advertisement
BMRN vs IBO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a Hold and IBO is a Hold.
BMRN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BMRN turned positive on October 20, 2026. Looking at past instances where BMRN's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMRN's RSI Indicator exited the oversold zone, 18 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on BMRN as a result. In 54 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in 162 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 65 cases where BMRN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
BMRN broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BMRN entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.718) is normal, around the industry mean (2.904). BMRN's P/E Ratio (151.676) is considerably higher than the industry average of (-0.738). Projected Growth (PEG Ratio) (0.348) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (3.727) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IBO's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for IBO turned positive on October 23, 2026. Looking at past instances where IBO's MACD turned positive, the stock continued to rise in 15 of 15 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IBO's RSI Indicator exited the oversold zone, 6 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on IBO as a result. In 32 of 41 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBO advanced for three days, in 72 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 16 of 19 cases where IBO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The 10-day moving average for IBO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IBO entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.254) is normal, around the industry mean (2.904). P/E Ratio (0.369) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. IBO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BMRN | IBO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 89 | 8 | |
PRICE GROWTH RATING 1..100 | 57 | 83 | |
P/E GROWTH RATING 1..100 | 1 | 79 | |
SEASONALITY SCORE 1..100 | 85 | 30 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IBO's Valuation (81) in the null industry is in the same range as BMRN (98) in the Biotechnology industry. This means that IBO’s stock grew similarly to BMRN’s over the last 12 months.
IBO's Profit vs Risk Rating (100) in the null industry is in the same range as BMRN (100) in the Biotechnology industry. This means that IBO’s stock grew similarly to BMRN’s over the last 12 months.
IBO's SMR Rating (8) in the null industry is significantly better than the same rating for BMRN (89) in the Biotechnology industry. This means that IBO’s stock grew significantly faster than BMRN’s over the last 12 months.
BMRN's Price Growth Rating (57) in the Biotechnology industry is in the same range as IBO (83) in the null industry. This means that BMRN’s stock grew similarly to IBO’s over the last 12 months.
BMRN's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for IBO (79) in the null industry. This means that BMRN’s stock grew significantly faster than IBO’s over the last 12 months.
| BMRN | IBO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 60% | 2 days ago 67% |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 66% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 19% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 90% |
| Advances ODDS (%) | 7 days ago 58% | 2 days ago 79% |
| Declines ODDS (%) | 3 days ago 62% | 7 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 61% | N/A |
| Aroon ODDS (%) | 2 days ago 60% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMRN’s FA Score shows that 1 FA rating(s) are green while IBO’s FA Score has 1 green FA rating(s).
- BMRN’s FA Score: 1 green, 4 red.
- IBO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMRN’s TA Score shows that 4 TA indicator(s) are bullish while IBO’s TA Score has 4 bullish TA indicator(s).
- BMRN’s TA Score: 4 bullish, 4 bearish.
- IBO’s TA Score: 4 bullish, 4 bearish.
Price Growth
BMRN (@Biotechnology) experienced а +2.02% price change this week, while IBO (@Biotechnology) price change was +2.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.72%. For the same industry, the average monthly price growth was -14.23%, and the average quarterly price growth was -21.13%.
Reported Earning Dates
BMRN is expected to report earnings on Feb 24, 2027.
IBO is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Biotechnology (-8.72% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GPZ | 24.22 | 1.32 | +5.74% |
| Vaneck Alternative Asset Manager ETF | |||
| SPCT | 28.88 | 0.79 | +2.82% |
| Liberty One Spectrum ETF (SPCT) | |||
| QAI | 35.71 | 0.23 | +0.65% |
| NYLIM Hedge Multi-Strategy Tracker ETF (QAI) | |||
| IJH | 74.59 | 0.46 | +0.62% |
| iShares Core S&P Mid-Cap ETF (IJH) | |||
| DAMD | 12.28 | -0.25 | -2.00% |
| Defiance Daily Target 2X Short AMD ETF (DAMD) | |||